Individuals who carry the apolipoprotein E "4 polymorphism have an increased risk of late-onset Alzheimer's disease. However, because possession of the "4 allele confers an increased risk for the diagnosis of dementia, it has proven problematic in older individuals to dissociate the influence of "4 on cognitive capacity per se as distinct from its influence on clinical diagnostic status. We report a statistical approach that attempts to partial out the influence of diagnostic group membership (Alzheimer's disease, mild cognitive impairment, healthy control) from the influence of apolipoprotein "4 genetic status on cognitive functioning. The cognitive phenotype hypothesis predicts that "4-positive individuals will show cognitive deficits (relative to matched "4-negative individuals) independent of the development of Alzheimer's disease. By contrast, the prodromal/preclinical Alzheimer's disease hypothesis proposes that the effect of apolipoprotein E status on cognitive performance is a function of the increased risk of dementia in individuals with the "4 allele. We evaluated these hypotheses in the Australian Imaging, Biomarkers and Lifestyle cohort (n = 1112). We first determined whether previously reported findings concerning "4 status and age-related neuropsychological performance could be explained by the inadvertent recruitment of people with mild cognitive impairment into the healthy control group. We then tested each diagnostic group in isolation to identify any neuropsychological patterns that may be attributed to the "4 allele. Finally, as interactions between the "4 allele and age have previously been reported in cognitive functioning within healthy elderly populations, we attempted to determine whether the inclusion of mild cognitively impaired individuals in the sample may drive this relationship. An extensive battery of standardized, wellvalidated neuropsychological tasks was administered to a final sample of 764 healthy control subjects, 131 individuals with mild cognitive impairment and 168 individuals with Alzheimer's disease. The effect of the "4 allele on cognitive performance was assessed using a statistical mediation analysis and supplemented with Bayesian methods to address a number of the limitations associated with Fisherian/Neyman-Pearsonian significance testing. Our findings support the prodromal/preclinical Alzheimer's disease hypothesis and do not support the concept of a distinctive "4-related cognitive phenotype.
Introduction
Individuals with the apolipoprotein E (APOE) "4 polymorphism have an increased risk of late-onset Alzheimer's disease (Corder et al., 1993; Saunders et al., 1993) . What is more contentious is whether healthy "4-positive older adults exhibit cognitive deficits relative to healthy "4-negative individuals, and whether any such deficits foreshadow the characteristic cognitive changes associated with the onset of dementia.
There are two main hypotheses concerning the influence of APOE status on cognition: (i) the preclinical/prodromal hypothesis (Smith et al., 1998; Negash et al., 2009) and (ii) the cognitive phenotype hypothesis (Greenwood and Parasuraman, 2003; Greenwood et al., 2005) . The prodromal/preclinical Alzheimer's disease hypothesis proposes that the effect of APOE status on cognitive performance is a function of the increased risk of dementia in individuals with the "4 allele, such that any differences that emerge between "4-positive and "4-negative elderly individuals on cognitive performance are driven by an increased number of people in the "4-positive sample with prodromal dementia. The prodromal "4 hypothesis therefore predicts small to very small "4 effect sizes on cognition, because any detectable effect in the non-demented "4-positive population would be due to cases of prodromal dementia that will only be present in some "4-positive individuals (as "4-positive is not deterministic for dementia). Furthermore, where individuals are thoroughly screened prospectively for preclinical dementia (or in some cases retrospectively screened for dementia), according to the prodromal hypothesis the cognitive differences between the "4-positive and "4-negative groups should be negligible.
By contrast, the cognitive phenotype hypothesis (Greenwood et al., 2005; Payton, 2009) conceptualizes the relationship between cognitive performance and APOE status as representing a product of the interaction between APOE status and neuronal response to insult accumulated over the lifetime (Greenwood and Parasuraman, 2003) , whereby the possession of the "4 allele induces increased neural damage along a continuum (such that increasing age in conjunction with the possession of the "4 allele leads to increasing magnitude of neurocognitive impairment). This hypothesis predicts that "4-positive individuals will show cognitive deficits (relative to matched "4-negative individuals) independent of the development of Alzheimer's disease, and is therefore consistent with larger "4-associated effect sizes on cognition (as this hypothesis proposes that cognitive deficits will be present across non-demented "4-positive individuals at large).
These two competing hypotheses offer different predictions for the outcomes of studies investigating the influence of the "4 allele on cognition in healthy elderly populations. However, the results of extant investigations into the effect of the "4 allele on patterns of age-related cognitive impairment have generally been inconsistent. Whereas some studies have reported subtle deficits in selective cognitive domains in "4-positive healthy elderly individuals (Bondi et al., 1995; Greenwood et al., 2000 Greenwood et al., , 2005 Caselli et al., 2001; Rosen et al., 2002; Wilson et al., 2002; Driscoll et al., 2005; Nilsson et al., 2006; Packard et al., 2007; Negash et al., 2007 Negash et al., , 2009 Zehnder et al., 2009; Liu et al., 2010) , other studies have failed to detect differences between "4 and non-"4 groups of healthy elderly people (Smith et al., 1998; Bondi et al., 1999; Juva et al., 2000; Reiman et al., 2001; Winnock et al., 2002; Bunce et al., 2004; Small et al., 2004; Duchek et al., 2006; Kleiman et al., 2006; Luciano et al., 2008; Carrió n-Baralt et al., 2009) . Two meta-analyses have indicated that episodic memory, executive function, perceptual speed and global cognitive functioning are impaired in "4-positive individuals Wisdom et al., 2011) . However, the effect sizes obtained in these studies have been small and of borderline statistical significance. With respect to the predictions of the two hypotheses, this pattern of inconsistent effects, small effect sizes and marginal statistical significance might reasonably be considered troublesome for the cognitive phenotype hypothesis. This is especially so considering that more than 20 000 participants have been tested on some of the cognitive domains mentioned. This point notwithstanding, we consider that statistical considerations may have produced a somewhat biased hypothesis testing environment (see below concerning the null hypothesis). One of our central goals in the current investigation was to address these issues directly by applying an innovative statistical approach to the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of ageing data set.
Perhaps the most compelling evidence provided against the cognitive phenotype hypothesis concerns findings that indicate the elimination of the "4 effect on task performance when retrospective screening has taken place (e.g. Bondi et al., 1999; Winnock et al., 2002; Bä ckman et al., 2004; Bunce et al., 2004; Hayden et al., 2009) . Moreover, the inadvertent intrusion of preclinical/prodromal Alzheimer's disease into the healthy subgroup appears to be a significant risk when one considers that the Alzheimer's disease prodromal period can extend between 10 and 12 years or possibly even longer (Elias et al., 2000; Amieva et al., 2008) . Furthermore, some studies have reported that the influence of the "4 allele on cognitive performance among healthy control subjects diminishes when older individuals who are at the tail end of the peak period of Alzheimer's disease incidence are tested Negash et al., 2009) . However, this effect is not always consistent within (Negash et al., 2009) or between (Wisdom et al., 2011) studies. There have also been reports of mildly superior performance in older individuals carrying an "4 allele (Carrió n- Baralt et al., 2009; Negash et al., 2009) . Taken together, these findings further suggest that the effect of "4 is likely to be significantly influenced by the proportion of individuals with prodromal/preclinical Alzheimer's disease in study populations. We sought to investigate this question directly in the current study.
The prodromal/preclinical hypothesis predicts no (or very little) difference in neuropsychological profile between "4-positive and "4-negative individuals in the population at large. To date, studies examining this hypothesis have relied upon failing to reject the null hypothesis as evidence for the null hypothesis. This is a problematic approach because null hypothesis significance testing tells one nothing about the evidence for the null hypothesis (as significance tests are conditional on the null being true, and when the null is true, they yield uniformly distributed P-values; Rouder et al., 2009; Johansson, 2011) . Compounded on this issue is the distinction between (i) statistically significant effects and (ii) clinically meaningful effects: small P-values can accompany small effect sizes given a large enough sample. Bayesian approaches (Kass and Raftery, 1995; Raftery, 1999) have been proposed as a solution to testing both differences and similarities predicted by hypotheses, because they are able to elicit direct support for one of two competing hypotheses even if one is null (Wagenmakers, 2007; Rouder et al., 2009) ; such an approach seems ideal in the present context.
A related issue in the "4 literature concerns whether APOE status significantly influences the pattern of neuropathology (and consequently the neuropsychological profile) in patients with dementia (Smith et al., 1998) . This proposal contrasts with hypotheses suggesting that the effect of the APOE gene is simply to increase the risk of dementia and/or influence the rate of progression of dementia without affecting the pathophysiology of the disease. Neuropathological findings in patients with Alzheimer's disease have generally indicated that the effect of the "4-positive allele is to increase the quantity or accelerate the accumulation of neurofibrillary tangles and senile plaques (Olichney et al., 1996; Tiraboschi et al., 2004; Mortimer et al., 2009) . Similar accelerations in the build-up of neurofibrillary tangles and senile plaques have also been found in non-demented "4-positive individuals (Warzok et al., 1998) . There is also some evidence to suggest a difference in cognitive profile across "4 categories in individuals with mild cognitive impairment or Alzheimer's disease (Smith et al., 1998; McGuinness et al., 2010) . However, these results have again not always been consistent (Kleiman et al., 2006) . This represented a further question of interest in the present study.
The AIBL cohort is well placed to address many of the limitations that exist in research that has been conducted to date into the impact of "4 status on age-related neuropsychological capacity. The AIBL cohort consists of 1112 individuals comprising three groups: healthy control subjects, individuals with Alzheimer's disease and individuals with mild cognitive impairment, many of whom are likely to be harbouring preclinical/prodromal Alzheimer's disease. These three groups of participants have been screened carefully and diagnosed by a multidisciplinary consensus panel of experienced academic clinicians. An extensive battery of standardized, well-validated neuropsychological tasks was administered to all participants. To address the statistical limitations present in the existing research conducted in this field, we undertook a statistical mediation analysis and also calculated Bayes factors and probabilities using the difference in Bayesian information criteria (BIC) values for the null and alternative models (Kass and Raftery, 1995; Raftery, 1999; Wagenmakers, 2007; Masson, 2011) .
Firstly, we attempted to determine whether an explanation for previous findings on "4 and neuropsychological performance could be offered with respect to the inadvertent recruitment of people with mild cognitive impairment into the healthy control group as predicted by the prodromal hypothesis. To test this possibility, we investigated whether previous findings reporting a significant effect of the "4 allele on episodic memory, global cognitive function, perceptual speed and executive function in a non-Alzheimer's disease sample would be replicated in the AIBL cohort (Aim 1a). Secondly, we tested whether any "4 effects on neuropsychological performance that we identified in the AIBL cohort across the combined healthy control and mild cognitively impaired groups were mediated by the inclusion of participants with mild cognitive impairment, and-if so-how much of the "4 effect could be attributed to the inclusion of participants with mild cognitive impairment (Aim 1b).
Following this mediation analysis (Aim 1b), we tested each diagnostic group in isolation to identify any neuropsychological patterns that may be attributed to the "4 allele (Aim 2). In particular, we were interested in whether: (i) "4-positive healthy control subjects; (ii) "4-positive participants with mild cognitive impairment; and (iii) "4-positive patients with Alzheimer's disease displayed worse performance (relative to "4-negative healthy control participants, "4-negative mild cognitive impairment and "4-negative Alzheimer's disease participants, respectively) on any of the cognitive domains tested.
Finally, as interactions between the "4 allele and age have previously been reported on episodic memory and global cognitive function in cognitively normal populations Wisdom et al., 2011) , we attempted to determine whether the inclusion of individuals with mild cognitive impairment in the study samples may drive this relationship (Aim 3).
Materials and methods

Participants
Participants comprised the cohort of 1112 individuals enrolled in the AIBL study of ageing. Extensive information on recruitment, screening and characterization of this cohort has previously been reported (Ellis et al., 2009) . This cohort consisted of 768 healthy control subjects, 133 individuals with mild cognitive impairment and 211 individuals with Alzheimer's disease. These three groups of participants had been screened carefully and diagnosed by a multidisciplinary consensus panel of experienced academic clinicians. All patients with Alzheimer's disease met National Institute of Neurological and Communicative Disorders-Alzheimer's disease and related disorders (NINCDS-ADRDA) criteria for probable or possible Alzheimer's disease. Mild cognitively impaired cases were diagnosed using the criteria of Winblad et al. (2004) , which are informed by the criteria proposed by Petersen et al. (1999) .
All participants classified as having mild cognitive impairment reported memory difficulties and, if they were referred to the study with a provisional classification of mild cognitive impairment made by a clinician, demonstrated at least one neuropsychological test score which was 1.5 SD below the age-adjusted mean. If a participant initially volunteered to take part in the study as a healthy control, to be classified as having mild cognitive impairment at least two of their neuropsychological test scores were required to be 1.5 SD below the age-adjusted mean. As can be seen from Table 1 , the mild cognitively impaired group performed at a considerably lower level than the healthy control group across the range of neuropsychological tests used in this study. The magnitude of this performance deficit in the individuals with mild cognitive impairment in the present study is on a par with several previous studies into the neuropsychological performance of individuals with mild cognitive impairment (Petersen et al., 1999; Geslani et al., 2005; Kramer et al., 2006; Ribeiro et al., 2007; Nutter-Upham et al., 2008) . A more detailed discussion of the diagnosis of mild cognitive impairment in the AIBL study is presented in Ellis et al. (2009) .
In addition to the clinical diagnostic criteria cited above, Pittsburgh compound B imaging results obtained from a subset of the cohort used in this study have been published (Villain et al. 2012) . Individuals with mild cognitive impairment were much more likely to be positive for Pittsburgh compound B (31/49, 63%) compared with healthy control subjects [32/103, 31%, odds ratio (OR) = 3.82 95% confidence interval (CI) = 1.89, 7.94]. Furthermore, 17 of 49 individuals with mild cognitive impairment progressed to Alzheimer's disease (35%) whereas only one healthy control individual progressed to Alzheimer's disease (Villain et al. 2012) over an 18-month period after completion of the study reported here.
Ethical approval for the study was obtained from the St Vincent's Hospital, Austin Health, Edith Cowan University and Hollywood Private Hospital Human Research Ethics Committees.
Cognitive and mood assessment
Detailed information on the cognitive and mood assessment of the AIBL cohort has previously been reported (Ellis et al., 2009) . Briefly, the battery of cognitive tests included the Mini-Mental State Examination (Folstein et al., 1975) , California Verbal Learning Test 2nd edition (CVLT-II) (Delis, 2000) , Logical memory I and II of the Wechsler memory scale (Story A only) (Wechsler, 1945) , Delis-Kaplan Executive Function System, Letter fluency, Category fluency and Category switching (Delis et al., 2001) , 30-item Boston Naming Test (Saxton et al., 2000) , Wechsler Test of Adult Reading (WTAR) (Wechsler, 2001) , Digit span and Digit symbol coding subtests of the Wechsler Adult Intelligence Scale 3rd edition WAIS (Wechsler, 1997) , the Stroop test (Victoria version) (Strauss et al., 2006) , the Clock drawing test (Freedman, 1994) and the Rey Complex Figure  Test (RCFT) (Meyers and Meyers, 1995) . To assess mood, the Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith, 1983) was given on the same morning as cognitive testing was administered. Finally, dementia severity was rated using the Clinical Dementia Rating (Morris, 1997) . All neuropsychological variables were entered into the analyses reported here as Z-or t-scores adjusted for age. The CVLT was also adjusted for gender and the Boston Naming Test was adjusted for years of education (as per relevant normative data).
Apolipoprotein E genotyping
Participants gave an 80 ml blood sample on arrival for the assessment session. Full details of the blood analyses can be found in Ellis et al. (2009) . APOE genotype was determined by direct sequencing using 0.5 ml of extracted blood.
Statistical analysis
Statistical analysis was performed in R version 2.151 (R Development Core Team, 2012) using a combination of null hypothesis significance testing, statistical mediation and a Bayes factor approximation. The mediation analysis proposed by Baron and Kenny (1986) requires three criteria to be fulfilled to establish a mediation effect: (i) there is a significant relationship between the independent variable ("4 allele) and the dependent variable (cognitive performance); (ii) there is a significant relationship between the independent variable ("4 allele) and the mediating variable (healthy control or mild cognitive impairment group membership); and (iii) the relationship between the independent variable ("4 allele) and the dependent variable (cognitive performance) must be reduced significantly when the mediating variable is included as a predictor of the dependent variable. These criteria were all fulfilled.
Although the Baron and Kenny (1986) method is a useful starting point for mediation analysis, it has a number of limitations (MacKinnon et al., 2007; Hayes, 2009) . Bootstrapping the estimate of the mediated effect has therefore been recommended for mediation analysis because the technique offers acceptable statistical power properties, directly estimates the mediated effect and does not rely on many of the assumptions necessary for other tests (MacKinnon et al., 2007; Hayes, 2009) . We calculated bootstrapped 95% CIs with bias correction using the difference in regression coefficients. This was undertaken by subtracting the coefficient for the direct effect of "4 (denoted c) on cognitive test performance from the coefficient for the effect of "4, while partialling out the variance associated with diagnostic category (denoted c'), resulting in the mediated effect (cÀc'). It has been shown that this method performs well with binary mediators (Li et al., 2007) , i.e. diagnostic category. The bootstrapped samples (10 000 replications) were stratified according to diagnostic grouping and "4 status. The statistical effect of the "4 allele was investigated assuming an allelic dosage model (possession of no "4 allele, "4 À/À = 0, possession of one "4 allele, "4 + /À = 1, possession of two "4 alleles, "4 + / + = 2; Corder et al., 1993; Balding, 2006) , with diagnostic status included in the model as a binary factor (healthy control, mild cognitive impairment). Because this analysis was aimed at quantifying how much the inclusion of participants with a diagnosis of mild cognitive impairment into the healthy control group may mediate any putative "4 effects on neuropsychological performance, patients with Alzheimer's disease were not included in the analysis. In addition to null hypothesis significance testing, evidence for or against the effect of the "4 allele on each cognitive test was supplemented with a Bayesian approximation. Bayesian methods are able to address a number of problems associated with Fisherian/Neyman-Pearsonian P-values (Kass and Raftery, 1995; Wagenmakers, 2007) . In particular, Bayesian methods are able to quantify support for the null hypothesis, because they 
Digit span scaled score 12.0 (2.9) 11.2 (2.7) 9.4 (2.9) Digit symbol coding scaled score 11.7 (2.6) 9.7 (2.9) 6.7 (2.8) D-KEFS Letter fluency Z-score 12.0 (2.6) 9.7 (2.9) 6.7 (2.8) Category fluency Z-score 12.4 (3.1) 9.0 (3.4) 5.5 (2.8) Category switching total Z-score 12.1 (3.2) 8.1 (3.5) 4.6 (3.1) Category switching accuracy Z-score 12.2 (3.0) can calculate the probability of a hypothesis conditional on the data, as opposed to significance testing, which calculates the probability of the data conditional on the null hypothesis being true. Significance testing can also overstate the evidence against the null hypothesis, giving a misleading impression of the evidence that the alternative hypothesis is favoured by the data (Berger and Sellke, 1987; Goodman, 1992; Wagenmakers, 2007; Rouder et al., 2009; Wetzels et al., 2011) . This may be especially problematic when the effect size for a particular hypothesis is relatively small (Ioannidis, 2005) . This feature of Fisherian/Neyman-Pearsonian significance testing is also problematic from a theoretical development viewpoint, as an inability to adequately identify invariances limits scientific progress (Rouder et al., 2009) . We were especially motivated to apply Bayesian methods given that one of the major limitations occurring to date in testing the prodromal/preclinical hypothesis is that this hypothesis predicts no difference (or very little difference) in neuropsychological profile in the population between "4-positive and "4-negative individuals.
In the analyses reported here and detailed in Tables 2-4 , a Bayesian approximation was therefore applied in addition to calculating Fisherian/Neyman-Pearsonian P-values for all of the reported analyses. We used the method outlined in Wagenmakers (2007) to calculate Bayes factors and probabilities by comparing the BIC values of the null hypothesis model (i.e. model without "4) and the alternative model (i.e. model with "4). This method assumes that the two models under consideration are equally plausible a priori, and yields an approximation of their posterior probabilities assuming a unit information prior (Raftery, 1999) .
General guidelines for the strength of evidence indicated by the posterior probability offered by the BIC approximation (P BIC ) are as follows: with respect to the null hypothesis, 0.50-0.75 is considered to be weak evidence in favour of this hypothesis; 0.75-0.95 is considered as positive evidence in favour; 0.95-0.99 is considered as strong evidence; and probabilities larger than 0.99 are considered to provide very strong evidence in favour of the null hypothesis. Support for the alternative hypothesis is similarly (but conversely) interpreted, i.e. a P BIC value of 0.50-0.25 is considered to be weak evidence for the alternative hypothesis; 0.25-0.05 is considered to be positive evidence in favour of this hypothesis; 0.05 to 0.01 is considered as strong evidence; and a P BIC -value 50.01 is considered to represent very strong evidence for the alternative hypothesis.
Results
Final sample
Participants were excluded from statistical analyses if they were unable to complete the Wechsler test of adult reading, as this provided a critical index of premorbid capacity, and in practice this measure was also a reliable indicator of whether individuals were willing and/or able to complete the remainder of the cognitive testing. APOE genotype information was not available for one participant with mild cognitive impairment and two Alzheimer's disease participants. This left 764 healthy control subjects, 131 participants with mild cognitive impairment and 168 individuals with Alzheimer's disease in the final sample. Demographic characteristics are presented in Table 1 .
Statistical mediation analysis: the effect of the "4 allele on cognitive performance in the healthy controls
Because one of our central aims was to determine the possible effect of incorporating mild cognitively impaired individuals into the healthy control category, the analysis in this section is focused on healthy control subjects. The first step of a mediation analysis is to establish whether there is an association between the independent variable and the dependent variable. When the mild cognitive impairment and the healthy control groups were combined, the "4 allele was associated with reduced cognitive performance across a range of cognitive variables (Table 2 ). Relating to the particular issue of whether global cognitive functioning, episodic memory, perceptual speed and executive functioning would be adversely affected by possession of the "4 allele (Aim 1a), there was very strong support for this proposal with respect to global cognitive functioning (Mini-Mental State Examination) and episodic memory (CVLT-II learning trials, Short-delay free recall, Long-delay free recall, Recognition discriminability d 0 , Recognition hits and false positives, RCFT 3 min delayed recall, 30 min delayed recall and item recognition, and Logical memory I and II recall), and there was positive support with respect to the perceptual speed measure (Digit-symbol coding). However, performance on the executive function measures showed inconsistent differences: Delis-Kaplan executive function system category switching total and accuracy indicated support for an effect of the "4 allele, while the Stroop interference measure demonstrated strong support for the null hypothesis. The second step of a mediation analysis is to identify whether there is a relationship between the independent variable ("4 status) and the mediating variable (diagnostic category). Binomial regression with diagnostic category as the dependent variable (healthy control, mild cognitive impairment) indicated that possession of one "4 allele increased the odds of categorization into the mild cognitive impairment group by 2.28Â (95% CI = 1.53-3.41) and the possession of two alleles increased the odds by 5.71Â (95% CI = 2.64-12.0). Adding years of education (OR "4 + /À = 2.34; OR "4 + / + = 5.99), age (OR "4 + /À = 2.38; OR "4 + / + = 8.23) or both of these variables (OR "4 + /À = 2.43; OR "4 + / + = 8.21) to the model did not substantially affect these relationships with respect to "4 status and odds of mild cognitive impairment categorization. The third step in a mediation analysis is to investigate whether the association between the independent variable and the dependent variable is significantly reduced when the mediating variable is included as a predictor in the model. The mediation analysis reported in Table 2 shows that the effect of the "4 allele on cognitive performance was reduced markedly when diagnostic category was included in the models (see the c-c' coefficients and intervals shown in Table 2 ). Further investigation revealed that a higher proportion of patients with mild cognitive impairment possessed an "4 allele compared to the healthy control subjects. The P BIC results in Table 2 also show that the null model with diagnostic category only as a predictor was more strongly supported than the model with both diagnostic category and APOE as predictors, indicating that the there was little (if any) effect of the "4 allele on neuropsychological performance across the healthy control and mild cognitive impairment groups independent of diagnostic status (Aim 1b).
Effect of the "4 allele within each diagnostic group
In addition to the mediation analysis reported above, when neuropsychological performance in healthy control individuals was analysed in isolation, the outcomes shown in Table 3 indicated that the null model was strongly supported over the model with "4 included (all P BIC on the main domains of interest 40.92). Only performance on the perceptual speed measure, Digit-symbol coding, indicated some positive support for the competing model which included "4 (P BIC = 0.15).
In the subgroup of patients with mild cognitive impairment, several measures within the episodic memory domain showed strong support for an adverse effect of the "4 allele (CVLT longdelay free recall, CVLT recognition discriminability d') while other measures indicated some positive support (CVLT short-delay free recall, CVLT recognition hits, Logical memory II, RCFT 3 min delayed recall). However, most measures summarized in Table 3 indicated stronger support for the null model within the mild cognitive impairment group, including performance on the Clock drawing test, CVLT false positives, Stroop, Boston Naming Test, Digit-symbol coding, Delis-Kaplan executive function system fluency measures, Hospital anxiety and depression scale and RCFT copy accuracy and copy time.
We also evaluated whether a distinctive cognitive phenotype was present in people diagnosed with Alzheimer's disease. In this subgroup, the analysis depicted in Table 3 showed that the simpler null model (i.e. without "4 included) was more strongly supported across all of the measures. No measure showed strong (or even positive) support for an adverse effect of the "4 allele. Performance on the RCFT 30 min delayed recall indicated equivocal support for both the null model (i.e. "4 not included in the model) and the alternative model that included the "4 allele.
The interaction between the "4 allele and age in healthy control subjects and participants with mild cognitive impairment
The aim of the analyses reported in this section was to examine whether previously identified "4 by age interactions on global cognitive functioning and episodic memory Wisdom et al., 2011) could be explained by the inadvertent inclusion of individuals with mild cognitive impairment in the healthy control category.
When both the healthy control subjects and participants with mild cognitive impairment were included in one analysis, there were a number of significant "4 by age interactions. alone and also for the healthy control group combined with the mild cognitive impairment group. Notably, in the combined healthy control subjects and mild cognitive impairment analysis, performance on the episodic memory measures (CVLT learning trials, Short-delay free recall, CVLT recognition discriminability d', CVLT false positives, Logical memory I and II, RCFT 3 and 30 min delayed recall) were shown to be disproportionately lower in "4-positive individuals compared with "4-negative individuals with increasing age. In addition, scores on the Mini-Mental State Examination were reduced more in "4-positive individuals compared with "4-negative individuals with increased age. However, when individuals with mild cognitive impairment were identified and excluded from the analysis, there was strong support among healthy control subjects for the null hypothesis of no age by "4 interaction across the episodic memory and global cognitive functioning domains (Table 4) . As education may influence the interaction between the "4 allele and age on cognitive performance, an ordinal logistic regression was performed to determine if there were any differences in education (treated as an ordered factor, with the groupings: 59, 9-12, 13-15 and 15 + years) between "4-positive and "4-negative individuals. There was no association between education and "4 status in the healthy control subjects (OR = 0.84, 95% CI = 0.63-1.12) or in the participants with mild cognitive impairment (OR = 0.71, 95% CI = 0.38-1.33). In the combined healthy control subjects and mild cognitively impaired group, "4-positive individuals were slightly more likely to have less education compared to "4-negative individuals (OR = 0.77, 95% CI = 0.60-1.00). However, this association was driven by participants with mild cognitive impairment being more likely to have less education (OR = 0.62, 95% CI = 0.44-0.87). Nevertheless, due to the possible association between education and the "4 allele, we re-analysed the age by "4 interactions with education included as a covariate for both (i) the healthy control and (ii) the healthy control plus mild cognitively impaired analyses cited above. The largest change that occurred was for the RCFT 3-min delay within the group that combined healthy control subjects and people with mild cognitive impairment, which changed from P BIC = 0.20 without education as a covariate to P BIC = 0.10 when including education as a covariate. The majority of the other changes represented less than a 0.03 change in the P BIC -value. Therefore, there were no marked changes in outcomes when education was included as a covariate.
Examining the influence of age adjustment
With respect to the aims of this study, a complementary set of analyses was conducted on the raw performance scores for all variables that had been converted to age-adjusted Z-or T-scores for the previously reported analyses (i.e. CVLT, RCFT, Logical memory, Delis-Kaplan executive function system and Stroop). These analyses yielded a very similar overall pattern of results to that reported for the normative adjusted scores presented previously. The only notable differences were seen for the Alzheimer's disease group, likely because the age differences between "4 À/À , "4 + /À and "4 + / + individuals with Alzheimer's disease were greater in this diagnostic group (see Supplementary Table 1 ). The variables in the Alzheimer's disease group that showed differences in P BIC between the age-adjusted and unadjusted scores were as follows: the RCFT 3 and 30 min delayed free recall raw scores indicated strong support for the null hypothesis, compared to the age-adjusted scores which showed no support for either the null or the experimental hypothesis (age adjusted P BIC $0.5, unadjusted P BIC $0.91); the Boston Naming Test scores changed from strong support for the null to positive support for an effect of the "4 allele (age adjusted P BIC = 0.88, unadjusted P BIC = 0.15); Category fluency scores indicated positive support for an effect of the "4 allele using the unadjusted scores compared to equivocal support for the either hypothesis using the age-adjusted scores (age adjusted P BIC = 0.58, unadjusted P BIC = 0.08). There were no noteworthy changes for any of the other neuropsychological variables when raw scores were analysed (compared with the age-adjusted scores). Table 4 Continued 
Discussion
Impact of "4 on neuropsychological performance in healthy control subjects
The first aim of this study was to evaluate whether previous findings concerning the impact of "4 on neuropsychological performance could be explained by the inadvertent assignment of individuals with mild cognitive impairment as 'healthy control subjects'. The evidence presented in this study strongly indicates that this was likely to have been the case in previous investigations. Specifically, when the healthy control subjects and the participants with mild cognitive impairment were combined in the one analysis in the present study, the "4 allele was strongly associated with reduced performance on several cognitive measures which have been cited in previous investigations of the "4 allele (Wisdom et al., 2011) . In particular, episodic memory measures, the global cognitive function measure (Mini-Mental State Examination), the perceptual speed measure (Digit-symbol coding) and one executive function measure (Delis-Kaplan executive function system category switching total and accuracy) all showed support for the negative impact of the "4 allele. However, the mediation analysis reported here demonstrated that when individuals with mild cognitive impairment were identified and the variance attributed to this group was partitioned out of the statistical model, the effect of the "4 allele reduced markedly. Indeed, when the healthy control subjects were analysed in isolation, the Bayesian approximation signified strong support for the null model, indicating no robust association between neuropsychological performance and the "4 allele on each of the episodic memory tasks that were administered in this study (all P BIC 4 0.95). This result contrasts with the meta-analysis findings reported by Small et al. (2004) and Wisdom et al. (2011) . The global cognitive functioning and executive functioning domains also showed strong support for the null hypothesis when the healthy control group was analysed in isolation, whereas the perceptual speed domain indicated equivocal support for an effect of the "4 allele. One explanation for the discrepancy between the current study and previous studies that have purported to demonstrate effects of APOE "4 status on neuropsychological capacity is that the current study sensitively identified individuals with mild cognitive impairment through a multi-disciplinary consensus panel of experienced clinicians, such that the healthy control group was thoroughly screened and did not manifest any features indicative of mild cognitive impairment. It is important to note, however, that the screening conducted in the present study still resulted in significant neuropsychological deficits in the mild cognitive impairment group that were of a magnitude consistent with many previous studies that have contrasted individuals with mild cognitive impairment to healthy control subjects (Petersen et al., 1999; Geslani et al., 2005; Kramer et al., 2006; Ribeiro et al., 2007; Nutter-Upham et al., 2008) . Additionally, the diagnostic criteria for self-referred participants with mild cognitive impairment in the present study was more stringent than for physician referred participants with mild cognitive impairment, perhaps biasing the present study somewhat towards an increased likelihood of an "4 effect being observed among healthy control subjects. We believe that this consideration strengthens the current findings.
It should be further noted that a proportion of the participants with mild cognitive impairment in the present study were significantly more likely to manifest supra-threshold levels of the amyloid radiotracer Pittsburgh compound B and subsequently convert to Alzheimer's disease (Villain et al. 2012) . By comparison, the majority of studies evaluated in Wisdom et al. (2011) did not identify and exclude participants with mild cognitive impairment, resulting in the likely recruitment of preclinical Alzheimer's disease individuals into the healthy control group. Other researchers have also suggested that "4-related cognitive deficits reported in dementia-free individuals may reflect an over-representation of preclinical/prodromal phase individuals in studies that have reported cognitive deficits among healthy control subjects (Bondi et al., 1999; Small et al., 2000; Winnock et al., 2002; Bä ckman et al., 2004; Bunce et al., 2004) . This suggestion has been supported by several studies that have demonstrated marked reductions in differential cognitive performance across APOE "4 groups when future dementia is retrospectively taken into account (Bondi et al., 1999; Winnock et al., 2002; Bä ckman et al., 2004; Bunce et al., 2004; Hayden et al., 2009) . For example, Bunce et al. (2004) excluded participants with dementia at baseline and participants who obtained a diagnosis of dementia at any of this study's two follow-up sessions, and found no differences in cognitive performance between the "4-positive and the "4-negative groups. Furthermore, the cognitive domains that have previously been associated with presence of an "4 allele in control participants are the same cognitive domains that are typically impaired in individuals with preclinical Alzheimer's disease (Bä ckman et al., 2005; Wisdom et al., 2011) . Taken in the context of our current findings, this suggests that the effect of the "4 allele is to increase the risk of Alzheimer's disease (consistent with the prodromal dementia hypothesis), rather than to produce a distinctive cognitive phenotype in non-demented persons.
Despite the apparent parsimony of the prodromal hypothesis with respect to previous and current findings, we acknowledge that there have been some studies that directly support the cognitive phenotype hypothesis. For example, Bretsky et al. (2003) found evidence of cognitive impairment in "4-positive individuals even though these researchers attempted to screen for possible preclinical Alzheimer's disease, seemingly supportive of the cognitive phenotype hypothesis. Nevertheless, these authors suggested another possible reason for their findings, i.e. an extended prodromal Alzheimer's disease period among individuals who, at first inspection, are considered to be healthy control subjects.
"4-related neuropsychological profile in mild cognitive impairment and Alzheimer's disease
The second aim of the study was to identify whether there were any "4 associated cognitive deficits within the clinical participant groups. In the Alzheimer's disease group, there was strong support for the null model on all of the neuropsychological measures (except for the RCFT 30 min delay, which demonstrated equivocal support for an "4 effect). In contrast to the previously discussed healthy control (Aims 1a and b) and Alzheimer's disease groups, the mild cognitive impairment group showed weak positive support for an effect of the "4 allele on some episodic memory measures (e.g. CVLT short-delay free recall, P BIC 5 0.26) and strong evidence for an effect of the "4 allele on CVLT long-delay free recall, CVLT recognition hits and CVLT recognition discriminability d' (P BIC 5 0.14). As this analysis used cross-sectional data from the AIBL study (and therefore its findings are not directly related to rates of cognitive decline across groups), the combined findings from the mild cognitive impairment and Alzheimer's disease groups lend support to the view that possession of the "4 allele may contribute to a greater degree of cognitive deficit in individuals at higher risk for developing Alzheimer's disease. However, once the mild cognitive impairment has worsened and a diagnosis of Alzheimer's disease has been made, there appears to be little further impact of the "4 allele on neuropsychological test performance.
In contrast to the present findings, which are derived from an examination of cross-sectional group differences, an increased rate of longitudinal decline in "4-positive individuals across all diagnostic categories has been found in several previous studies (Yaffe et al., 1997; Kanai et al., 1999; Martins et al., 2005; Packard et al., 2007; Cosentino et al., 2008) . However, there have also been a number of reports indicating no differences in the rate of longitudinal decline between "4-positive and "4-negative individuals across diagnostic categories (Winnock et al., 2002; Bunce et al., 2004) , and some studies even reporting a reduced rate of decline in "4-positive individuals (Hoyt et al., 2005) . Differences in rates of declines reported amongst these studies could be a function of variability in disease severity, time of disease onset and length of follow-up time in studied individuals (Payton, 2009). Interaction between age and the "4 allele on cognitive ageing
The third aim of the study was to identify whether previous findings of an effect of the "4 allele on cognitive performance that varied as participants aged could also be attributed to inadvertent recruitment of mild cognitively impaired individuals into the healthy control group in previous investigations. In particular, Wisdom et al. (2011) found larger "4 effect sizes on episodic memory and global cognitive ability as age increased, whereas an opposite effect was found in a previous meta-analysis conducted by Small et al. (2004) . In the present study, when both healthy control subjects and participants with mild cognitive impairment were included in the analysis the episodic memory and global cognitive function results were consistent with Wisdom et al. (2011) in showing increased "4-positive-associated deficits with age.
The age Â "4 interaction findings reported here appear to be driven by the inclusion of participants with mild cognitive impairment in our analyses. When we excluded individuals who had been diagnosed with mild cognitive impairment, we found strong support for the null hypothesis (rather than for an age by "4 interaction) for both the episodic memory measures and the Mini-Mental State Examination within the healthy control group. This finding is consistent with the suggestion that preclinical/prodromal Alzheimer's disease (or mild cognitive impairment) individuals may not be consistently identified in study populations (Wisdom et al., 2011) . The results presented here provide further support for this suggestion.
Strengths and limitations
The results in the present study offer several advantages over previous efforts to investigate "4 allele associated effects on neuropsychological capacity. First, the mediation analysis used here was able to quantify directly how much of any observed "4 effect may have been due to the influence of data obtained in "4-positive participants with mild cognitive impairment. Therefore, we were able to evaluate the degree to which previous findings concerning the impact of "4 on neuropsychological performance could be explained by the inadvertent assignment of individuals with mild cognitive impairment to the healthy control group. Second, Bayesian analysis does not suffer from problems associated with null hypothesis testing, in contrast to Fisherian/ Neyman-Pearsonian significance testing. This is important, because previous studies that have concluded that there is no effect of the "4 allele on neuropsychological performance have relied on failing to reject the null hypothesis in order to quantify support for the null hypothesis. Third, the battery of neuropsychological tests administered in the current investigation was comprehensive. Indeed, all of the relevant cognitive domains that have been previously reported to be associated with the "4 allele in the major studies published by Wisdom et al. (2011) and Small et al. (2004) were evaluated. A limitation of the current study is that the analysis reported here is cross-sectional in nature. Longitudinal analyses are better placed to answer questions about the rate of cognitive decline in "4-positive participants with mild cognitive impairment compared to "4-negative participants with mild cognitive impairment. A further limitation is that the AIBL cohort represents a volunteer sample of the population, with such samples often manifesting somewhat different characteristics (e.g. more years of education) than the population at large.
Conclusion
Overall, the pattern of results from this study supports the proposal that the association of the "4 allele with age-related cognitive performance is limited to an increased risk of dementia in individuals who possess the "4 allele. The evidence reported here does not support the concept of a distinctive "4-related cognitive phenotype in non-demented populations or in patients with a diagnosis of Alzheimer's disease. Instead, the findings suggest that age-related cognitive impairment that has previously been associated with the "4 allele is due to an increased risk of clinical diagnosis with mild cognitive impairment or Alzheimer's disease in individuals who possess the "4 allele. APOE "4 profiling is likely to be most useful in providing early screening for mild cognitive impairment/Alzheimer's disease when it is combined with the administration of sensitive measures of cognitive performance.
